IMR Shares Imricor Medical Systems, Inc.
ACCUMULATE ASX · ASXPotential regulatory and clinical milestones could accelerate adoption of its cardiac imaging technology.
Future value: $2.95 (+127.24%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Upcoming clinical and regulatory milestones
- ▾Below 50-day MA (-23.49%)
- ▾Near 52-week low (2.6% of range)
- ▸~127% upside to price target
Is IMR a buy right now?
Trend: IMR is trading below the 50-day average (-20.83%), RSI 58 — neutral momentum, with a 3-month return of -29.44%.
Valuation & quality: Imricor Medical Systems, Inc. trades on forward P/E -13.1, price-to-book 11.40; fundamentals show net margin 0.0%, return on equity -143.1%, revenue growth -7.1% year on year.
Analyst consensus: 4 analysts have a mean 12-month price target of A$2.95 (+127.2% vs the last close; range A$2.32 – A$3.37), consensus rating “strong buy”.
Our screen: ACCUMULATE (score 1) — Potential regulatory and clinical milestones could accelerate adoption of its cardiac imaging technology.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -9.80% | +2.10% | -11.60% | +5.70% | +0.50% | +4.80% | -18.50% | -16.40% |
Fundamentals
Analyst price target
Technical signals
About Imricor Medical Systems, Inc.
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East.
Sector: Healthcare · Industry: Medical Devices · United States · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.